New Possibilities for Hormonal Vaginal Treatment in Menopausal Women

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Jul 29

PMID 37510854

Authors

Katarzyna Tomczyk

Karolina Chmaj-Wierzchowska

Katarzyna Wszolek

Maciej Wilczak

Affiliations

Soon will be listed here.

Abstract

Hormonal vaginal therapy is an effective treatment option for women who experience vaginal symptoms related to hormonal changes. Estrogen and prasterone are widely used as vaginal treatments, particularly for urogenital atrophy. These symptoms may include vaginal dryness, itching, burning, and pain during sexual intercourse, all of which can significantly affect a woman's quality of life. Previous studies have indicated that such treatment improves tissue elasticity, moisturizes the vagina, and can have a substantial impact on urine incontinence and vaginal microflora and decreases dyspareunia. Hormonal therapy is also useful and commonly used before vaginal surgical treatment. Prasterone is quite a new option for vaginal therapy in Poland and is mainly recommended for dyspareunia in menopausal women. The study related to prasterone therapy emphasizes its effectiveness and safety, making it advantageous to explore its beneficial impact. This paperwork aims to summarize the mechanism of action as well as the effects of both drugs and their beneficial action during vaginal treatment.

Citing Articles

Vaginal Microbiome: Environmental, Biological, and Racial Influences on Gynecological Health Across the Lifespan.

Dube-Zinatelli E, Cappelletti L, Ismail N Am J Reprod Immunol. 2024; 92(6):e70026.

PMID: 39670915 PMC: 11640209. DOI: 10.1111/aji.70026.

Experts' view on the role of oestrogens in combined oral contraceptives: emphasis on oestetrol (E4).

Creinin M, Cagnacci A, Spaczynski R, Stute P, Chabbert-Buffet N, Korver T Front Glob Womens Health. 2024; 5:1395863.

PMID: 38655395 PMC: 11035732. DOI: 10.3389/fgwh.2024.1395863.

References

Palma F, Volpe A, Villa P, Cagnacci A . Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study. Maturitas. 2015; 83:40-4. DOI: 10.1016/j.maturitas.2015.09.001. View

Amabebe E, Anumba D . The Vaginal Microenvironment: The Physiologic Role of . Front Med (Lausanne). 2018; 5:181. PMC: 6008313. DOI: 10.3389/fmed.2018.00181. View

Griebling T, Liao Z, Smith P . Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. Menopause. 2011; 19(6):630-5. PMC: 3319450. DOI: 10.1097/gme.0b013e31823b8983. View

Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A . A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med. 2010; 7(3):1284-90. DOI: 10.1111/j.1743-6109.2009.01667.x. View

Davison S, Davis S . Androgens in women. J Steroid Biochem Mol Biol. 2003; 85(2-5):363-6. DOI: 10.1016/s0960-0760(03)00204-8. View

Labrie F, Archer D, Bouchard C, Girard G, Ayotte N, Gallagher J . Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas. 2015; 81(1):46-56. DOI: 10.1016/j.maturitas.2015.02.005. View

Webb S, Geoghegan T, Prough R, Miller K . The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev. 2006; 38(1-2):89-116. PMC: 2423429. DOI: 10.1080/03602530600569877. View

Smith S, Ravel J . The vaginal microbiota, host defence and reproductive physiology. J Physiol. 2016; 595(2):451-463. PMC: 5233653. DOI: 10.1113/JP271694. View

Chee W, Chew S, Than L . Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health. Microb Cell Fact. 2020; 19(1):203. PMC: 7648308. DOI: 10.1186/s12934-020-01464-4. View

10.

Yu X, He L, Wang Y, Wang L, Yang Z, Lin Y . Local Estrogen Therapy for Pelvic Organ Prolapse in Postmenopausal Women: A Systematic Review and Meta-Analysis. Iran J Public Health. 2022; 51(8):1728-1740. PMC: 9546820. DOI: 10.18502/ijph.v51i8.10255. View

11.

Hosseinzadeh P, Ghahiri A, Daneshmand F, Ghasemi M . A comparative study of vaginal estrogen cream and sustained-release estradiol vaginal tablet (Vagifem) in the treatment of atrophic vaginitis in Isfahan, Iran in 2010-2012. J Res Med Sci. 2016; 20(12):1160-5. PMC: 4766822. DOI: 10.4103/1735-1995.172983. View

12.

Rahn D, Good M, Roshanravan S, Shi H, Schaffer J, Singh R . Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. J Clin Endocrinol Metab. 2014; 99(10):3728-36. PMC: 4184065. DOI: 10.1210/jc.2014-1216. View

13.

Mulholland S, Qureshi S, Fritz R, Silverman H . Effect of hormonal deprivation on the bladder defense mechanism. J Urol. 1982; 127(5):1010-3. DOI: 10.1016/s0022-5347(17)54176-2. View

14.

Leyva-Gomez G, Del Prado-Audelo M, Ortega-Pena S, Mendoza-Munoz N, Urban-Morlan Z, Gonzalez-Torres M . Modifications in Vaginal Microbiota and Their Influence on Drug Release: Challenges and Opportunities. Pharmaceutics. 2019; 11(5). PMC: 6571606. DOI: 10.3390/pharmaceutics11050217. View

15.

Colla Ruvolo C, Gabrielli O, Formisano C, Califano G, Manna P, Venturella R . Prasterone in the treatment of mild to moderate urge incontinence: an observational study. Menopause. 2022; 29(8):957-962. DOI: 10.1097/GME.0000000000002007. View

16.

Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R . Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014; 74(11):1195-207. DOI: 10.1007/s40265-014-0259-8. View

17.

Davis S, McCloud P, Strauss B, Burger H . Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995; 21(3):227-36. DOI: 10.1016/0378-5122(94)00898-h. View

18.

Aldunate M, Srbinovski D, Hearps A, Latham C, Ramsland P, Gugasyan R . Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Front Physiol. 2015; 6:164. PMC: 4451362. DOI: 10.3389/fphys.2015.00164. View

19.

Panjari M, Davis S . Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas. 2011; 70(1):22-5. DOI: 10.1016/j.maturitas.2011.06.005. View

20.

Torcia M . Interplay among Vaginal Microbiome, Immune Response and Sexually Transmitted Viral Infections. Int J Mol Sci. 2019; 20(2). PMC: 6359169. DOI: 10.3390/ijms20020266. View